These results and the dose-dependent efficacy shown in a mouse orthotropic intracranial IDH-wild type glioma model suggest that 1A-116 may be a useful novel therapeutic agent for glioma treatment, highlighting Rac1 as a valuable target in glioma. This evidence concerns the gene RAC1 and central nervous system cancer.